Center for Evidence-Based Imaging, Brigham and Women's Hospital, Boston, Massachusetts; Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts; Department of Imaging, Dana-Farber Cancer Institute, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
Center for Evidence-Based Imaging, Brigham and Women's Hospital, Boston, Massachusetts; Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
J Am Coll Radiol. 2018 Aug;15(8):1133-1138. doi: 10.1016/j.jacr.2018.04.008. Epub 2018 May 19.
The aim of this study was to use machine learning to predict abdominal recurrence on CT on the basis of serial cancer antigen 125 (CA125) levels in patients with advanced high-grade serous ovarian cancer on surveillance.
This institutional review board-approved, HIPAA-compliant, retrospective, hypothesis-generating study included all 57 patients (mean age, 61 ± 11.2 years) with advanced high-grade serous ovarian cancer who underwent cytoreductive surgery from January to December 2012, followed by surveillance abdominopelvic CT and corresponding CA125 levels. A blinded radiologist reviewed abdominopelvic CT studies until recurrence was noted. Four measures of CA125 were assessed: actual CA125 levels at the time of CT, absolute change since prior CT, relative change since prior CT, and rate of change since prior CT. Using machine learning, support vector machine models were optimized and evaluated using 10-fold cross-validation to determine the CA125 measure most predictive of abdominal recurrence. The association of the most accurate CA125 measure was further analyzed using Cox proportional-hazards model along with age, tumor size, stage, and degree of cytoreduction.
Rate of change in CA125 was most predictive of abdominal recurrence in a linear kernel support vector machine model and was significantly higher preceding CT studies showing abdominal recurrence (median 13.2 versus 0.6 units/month; P = .007). On multivariate analysis, a higher rate of CA125 increase was significantly associated with recurrence (hazard ratio, 1.02 per 10 units change; 95% confidence interval, 1.0006-1.04; P = .04).
A higher rate of CA125 increase is associated with abdominal recurrence. The rate of increase of CA125 may help in the selection of patients who are most likely to benefit from abdominopelvic CT in surveillance of ovarian cancer.
本研究旨在利用机器学习,根据接受监测的晚期高级别浆液性卵巢癌患者的连续癌抗原 125(CA125)水平,预测 CT 上的腹部复发。
本研究为机构审查委员会批准、符合 HIPAA 规定、回顾性、产生假说的研究,纳入了 2012 年 1 月至 12 月期间接受细胞减灭术且随后接受腹部盆腔 CT 监测和相应 CA125 水平检查的所有 57 例晚期高级别浆液性卵巢癌患者(平均年龄 61 ± 11.2 岁)。一位盲法放射科医生审查了腹部盆腔 CT 研究,直到出现复发。评估了 CA125 的 4 个指标:CT 时的实际 CA125 水平、与前一次 CT 相比的绝对变化、与前一次 CT 相比的相对变化和与前一次 CT 相比的变化率。利用机器学习,通过 10 倍交叉验证优化和评估支持向量机模型,以确定对腹部复发最具预测性的 CA125 指标。利用 Cox 比例风险模型分析与年龄、肿瘤大小、分期和细胞减灭程度相关的最准确 CA125 指标的关联。
在具有线性核支持向量机模型中,CA125 的变化率对腹部复发的预测最为准确,并且在 CT 研究显示腹部复发之前显著更高(中位数分别为 13.2 与 0.6 单位/月;P =.007)。在多变量分析中,CA125 增加率较高与复发显著相关(风险比,每增加 10 个单位变化 1.02;95%置信区间,1.0006-1.04;P =.04)。
CA125 增加率较高与腹部复发相关。CA125 增加率可能有助于选择最有可能从卵巢癌监测中的腹部盆腔 CT 中获益的患者。